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1. Introduction
Atherosclerotic cardiovascular disease and atrial fibrillation (AF) are causes of increased
mortality and morbidity all over the world. Coexistence of both leads to even higher rates of
mortality and morbidity. In AF, the main reason responsible for increased mortality and
morbidity is thromboembolisation and consequently the development of a stroke [1].
Among patients with atrial fibrillation, the incidence of atherosclerotic cardiovascular dis‐
ease has been reported to be 20-30% [2]. Thus, development of an acute coronary syndrome
(ACS) requiring percutaneous coronary intervention is very probable in patients with atrial
fibrillation. Despite a 17% reduction in the incidence of stroke with aspirin compared to pla‐
cebo, vitamin K antagonist (VKA) warfarin is superior to both aspirin and aspirin plus clopi‐
dogrel combinations due to its preventing AF patients from thromboemboli [3]. While triple
antithrombotic therapy (VKA+aspirin+clopidogrel) lowers the risk of stroke in stent im‐
planted patients with AF, it increases the risk of bleeding at long- term. Thus careful judge‐
ment of the risk of emboli and bleeding, the stent type (drug eluted or bare metal) to be
implanted and the duration of appropriate treatment regimen is important.
2. The evaluation of embolic risk
In patients with atrial fibrillation the main goal of antithrombotic therapy is to prevent
stroke. In patients with non-valvular AF, the atherosclerotic cardiovascular disease (espe‐
cially a history of myocardial infarction) has been found to be associated with an increased
incidence of stroke. Other important risks factors are diabetes, hypertension, previous
stroke/ transient ischemic attack and age. In patients with non valvular AF CHADS2DS2-
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Vasc-Score [6] derived from a European Heart Survey were found to be beneficial for esti‐
mation of the risk of stroke. This scoring system is suggested for risk stratification in both
the European Society of Cardiology (ESC) [7] and the American College of Cardiology/
American Heart Association (ACC/AHA) [8] guidelines. (Table1). According to this scoring
system, the patients are stratified into three risk groups as low (0), medium (1 – 2) and high
(>2). While the risk of emboli is 1.3 % at score 1, the risk increases to 15.2 % at score 9. While
previous embolism/TIA/stroke and age ≥75 are the major risk factors, the other clinical situa‐
tions are classified as the non-major risk factors. Not only previous myocardial infarction
but also complex atheroma plaques and peripheral vascular disease have also been included
in the definition of vascular disease.
Letter Clinical Condition and age Points
C Congestive heart failure† 1
H Hypertension 1
A Age≥75 years 2
D Diabetes mellitus 1
S Stroke/TIA/Thromboembolism 2
V Vascular disease* 1
A Age 65 – 74 1
S Female sex 1
max. 9 points
†Heart failure or moderate to severe left ventricular systolic dysfunction (e.g. LV EF < 40%)
*Prior myocardial infarction, peripheral artery disease, aortic plaque. TIA =transient ischaemic attack.
Table 1. CHA₂DS₂-Vasc-Score for determining embolic risk
3. Bleeding risk evaluation
In choosing the antithrombotic therapy regime, both the risk of bleeding and the evaluation
of thromboembolic risk are important. The use of VKA causes a more meaningful decrease
in embolic risk compared to aspirin alone or DAPT (dual antiplatelet therapy) in patients
with a medium and high risk. However the use of VKA increases the risk of major bleeding
especially when used with DAPT. Therefore, determining the risk of bleeding is important
before starting the therapy. Although various risk scores evaluating the risk of bleeding
have been obtained, they were all developed to estimate the risk of major bleeding and they
can be classified into three groups as low, medium and advanced. ESC guidelines recom‐
mend using HAS-BLED scoring [Table 2] (hypertension, abnormal renal/liver function,
stroke, bleeding history or predisposition, labile INR, elderly (>65), drugs/alcohol concomi‐
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tantly) in the estimation of bleeding risk [9]. HAS-BLED≥3 was found to be related to high
risk of bleeding. However, parameters such as a history of stroke, old age, and hypertension
also affect the risk of emboli estimated by using the CHA₂DS₂-Vasc-Score,. Thus, patients
with a high bleeding risk must be carefully managed.
Letter Clinical characteristic* Point
H Hypertension 1
A Abnormal renal or liver function (1 point each) 1 or 2
S Stroke 1
B Bleeding history 1
L Labile INR 1
E Elderly ("/>65 years) 1
D Drugs or alcohol comsumption (1 point each) 1 or 2
Max 9 poits
*Hypertension’ is defined as systolic blood pressure >160 mmHg. ‘Abnormal kidney function’ is defined as the pres‐
ence of chronic dialysis or renal transplantation or serum creatinine ≥200 mmol/L. ‘Abnormal liver function’ is defined
as chronic hepatic disease (e.g. cirrhosis) or biochemical evidence of significant hepatic derangement (e.g. bilirubin >2
x upper limit of normal, in association with aspartate aminotransferase/alanine aminotransferase/alkaline phospha‐
tase >3 x upper limit normal, etc.). ‘Bleeding’ refers to previous bleeding history and/or predisposition to bleeding, e.g.
bleeding diathesis, anaemia, etc. ‘Labile INRs’ refers to unstable/high INRs or poor time in therapeutic range (e.g.,
60%). Drugs/alcohol use refers to concomitant use of drugs, such as antiplatelet agents, non-steroidal anti-inflamma‐
tory drugs, or alcohol abuse, etc. INR = international normalized ratio. Adapted from Pisters et al (9).
Table 2. HAS-BLED bleeding score
4. Choosing antithrombotic therapy
In coronary artery disease, DAPT has been found superior to aspirin plus oral anticoagulant
(OAC) therapy in preventing recurrent ischemic events [10]. Although, in a long term peri‐
od, OAC therapy has been found superior to DAPT in AF patients, this therapy, especially
in situations when it must be combined with DAPT, has a major bleeding incidence of up to
4.7 %. This bleeding usually happens within the first month and has been fatal in almost half
of the patients [11]. Therefore, the management of patients with nonvalvular AF who re‐
quire PCI (percutaneous coronary intervention) is very important for many clinicians.
Nowadays, therapy guidelines include a therapy of low aspirin dose or no therapy for low
risk patients, OAC or aspirin for medium risk patients, and a therapy of OAC in patients
with a high risk. In medium risk patients, DAPT has been found inequivalent to VKA in
studies conducted on DAPT therapy (aspirin+ clopidogrel). VKA is related to lower bleed‐
ing and stroke. Therefore, in medium and high thromboli risk patients, if the risk of hemor‐
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rhage is high, because of the high incidence of intracranial and extra cranial bleeding
incidence, the option of DAPT should not be preferred.
In the abovementioned patients the low dose dabigatran option must be considered and if
they are treated with VKA, a lower INR (1.8-2.5) target should be chosen. However accord‐
ing to the studies made, patients with an INR <2 have double the risk of stroke compared to
patients whose INR is > 2.
5. Choosing therapy following elective percutaneous coronary
intervention
In elective percutaneous coronary interventions (PCI), if there is no obligatory indication
(long lesion, small vessel, diabetes, etc.) the intervention must be limited to a bare metal
stent (BMS). Because after the implantation of a drug eluting stent (DES), there is a require‐
ment for a triple antiplatelet for a longer time (3 months for sirolimus, 6 months for paclitax‐
el) and this may lead to a higher mortality rate associated with increased bleeding risk.
While the post BMS triple anti platelet therapy is limited to a 4 week period, it has to be
used longer following DES. In patients with low-medium bleeding risk but low embolic risk,
during the first four weeks after BMS, triple anti platelet therapy is suggested. After 4
weeks, lifelong OAC (INR=2-3) should be preferred. As an approach, there is a difference
between ESC guidelines and USA clinical practice [12]. In patients with low-medium hemor‐
rhagic risk both the ESC and the USA approaches suggest triple anti platelet therapy for
BMS and DES, but in the USA approach, only DAPT is suggested in patients with a high
bleeding risk. However, in ESC guidelines, despite the high bleeding risk, during the 2-4
week interval after BMS elective implantation, triple anti platelet therapy is advised.
Atrial fibrillation plus 
Coronary artery stent
High risk of stroke? 
CHADS   >1
High risk of bleeding?
Triple therapy
(Aspirin + OAC + Clopidogrel)
DAPT (Aspirin + Clopidogrel)
Yes
Yes
No
No
Figure 1. US Approach-Adapted from Paikin et al [12]
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As a therapy regime, OAC (INR=2 – 2.5), aspirin daily ≤100 mg and clopidogrel 75 mg daily
is included. In patients with a high risk of bleeding, it has been stressed in both guidelines
that DES should be avoided and if possible BMS should be implanted. Among patients hav‐
ing a low and medium bleeding risk, for those who have been implanted BMS, 1 month of
triple anti platelet therapy is advised. Among those patients who are DES implanted, for the
limus group, 3 months of triple antiplatelet therapy is advised while for the paclitaxel
group, 6 months of DAPT is advised. Furthermore, in DES implanted patients, a dual thera‐
py of OAC plus aspirin up to 1 year or OAC plus clopidogrel is advised and after 1 year
only OAC mono therapy is advised. Therefore, DES implantation should be avoided be‐
cause it requires long term dual and triple therapy (Table3).
Hemorrhagic risk Clinic Stent type Anticoagulation regime
Low-Medium
HAS-BLED (0 – 2)
Elective BMS 1 month: triple therapy of warfarin (INR 2.0–2.5) + aspirin ≤ 100
mg/day + clopidogrel 75 mg/day
Lifelong: warfarin (INR 2.0–3.0) alone
Elective DES 3 (-olimus group) to 6 (paclitaxel) months: triple therapy of warfarin
(INR 2.0–2.5) + aspirin ≤ 100 mg/day + clopidogrel 75 mg/day
Up to 12 months: combination of warfarin (INR 2.0–2.5) + clopidogrel
75 mg/day (or aspirin 100 mg/day)*
Lifelong: warfarin (INR 2.0–3.0) alone
ACS DES/BMS 6 months: triple therapy of warfarin (INR 2.0–2.5) + aspirin ≤ 100 mg/
day + clopidogrel 75 mg/day
Up to 12 months: combination of warfarin (INR 2.0–2.5) + clopidogrel
75 mg/day (or aspirin 100 mg/day)*
Lifelong: warfarin (INR 2.0–3.0) alone
High
HAS-BLED (≥3)
Elective BMS 2–4 weeks: triple therapy of warfarin (INR 2.0–2.5) + aspirin ≤ 100
mg/day + clopidogrel 75 mg/day
Lifelong: warfarin (INR 2.0–3.0) alone
ACS BMS 4 weeks: triple therapy of warfarin (INR 2.0–2.5) + aspirin ≤ 100 mg/
day + clopidogrel 75 mg/day
Up to 12 months: combination of warfarin (INR 2.0–2.5) + clopidogrel
75 mg/day (or aspirin 100 mg/day); mg/day)*
Lifelong: warfarin (INR 2.0–3.0) alone
ACS=Acute coronary syndrome, BMS=Bare metal stent, DES=Drug eluted stent, INR=International normalized ratio
*Combination of warfarin (INR 2.0–2.5) + aspirin ≤ 100 mg/day may be considered as an alternative.
Drug-eluting stents should be avoided.Adapted from Lip et al
Table 3. ESC suggestions for anticoagulation in patients with coronary stent who have medium and high emboli risk
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6. Acute coronary syndrome
In patients with non-valvular AF who have acute coronary syndrome (ACS), the puncture
site for PCI is important. In anti- coagulated patients, how the therapy will be conducted in
the hospital and choosing the right type of stent bears an importance. As for those patients
who are not anti coagulated, the antithrombotic therapy during discharge is important. In
anticoagulated patients, femoral intervention is an independent predictor for major hemor‐
rhage and other vascular complications and therefore in those patients radial intervention is
preferred because it causes less bleeding and better results [13,14].
In patients with ACS, especially those in whom primary PCI have been applied, BMS should
be preferred because it requires a shorter duration triple antithrombotic therapy. OAC
should be given to non-STEMI patients when they are hospitalized and DAPT and heparin
should be given to those patients who have no therapy. If the thromboembolic risk is too
high, OAC therapy might as well be started in those patients during in-hospital period.
There are two approaches for patients who receive OAC during hospitalization. The first
and mostly used approach in clinical practice is the bridge therapy which involves stopping
OAC therapy and starting heparin. The second approach is to continue OAC therapy so that
INR will be in the 2-2.5 interval. The main drawback of the bridge therapy is when the ther‐
apy is stopped and then restarted, Protein –C and –S are not suppressed, and they increase
embolic complications paradoxically in patients with a very high emboli risk [15]. Therefore,
in patients with ACS having a very high embolic risk, it is advised that DAPT should be
added to the therapy without stopping OAC and without adding heparin (if the INR <2,
then heparin may be added) [16,17]. In STEMI patients for whom P-PCI is applied, if the
INR is within the interval of 2 – 3, then a similar approach is applicable. However, glycopro‐
tein (GP) IIb/IIIa inhibitors may have to be used due to the high thrombus burden. In those
patients with a high thrombus burden, if the INR>2, then GP IIb/IIIa inhibitor must not be
started, and, if possible thrombectomy should be considered instead. Alternatively, in pa‐
tients with INR<2, bivaluridin might be considered for use instead of GP IIb/IIIa inhibitor +
heparin. Due to high hemorrhagic risks, in patients using OAC and having optimal INR, ad‐
ditional heparin should not be used. In patients whose bleeding risk is high, triple therapy
should not be used for more than 1 month. Due to the need for short triple therapy, BMS
should always be preferred. Following ACS, triple therapy should be given for 1 month, du‐
al therapy including OAC should be given up to 12 months, and after 12 months only OAC
should be given lifelong. The short and long term antithrombotic therapy regimen of the
ACS patients is summarized in table 3.
Advice On Decreasing Hemorrhagic Risk:
1. The balance between hemorrhagic risk and embolic risk should be maintained very
well.
2. No therapy may be given to patients who are under 65 years of age having a low em‐
bolic risk.
3. In combined therapies, the dose of aspirin should be kept low (75 – 100 mg).
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4. In patients having a high bleeding risk hypertension should be treated aggressively.
5. Hepatic and renal functions should be followed closely in patients who take OAC.
6. In case of stent requirement, BMS should be preferred as much as possible.
7. During ACS, additional heparin, GP IIb/IIIa inhibitor or bivaluridin should not be given
to those patients who have an effective INR and who take OAC.
8. Radial intervention should be applied to patients who take OAC and who are inter‐
vened with STEMI.
9. Triple antiplatelet therapy should not be used for more than 1 month in patients whose
bleeding risk is high.
10. DAPT should not be given for a long time, instead only OAC should be given in long
term therapy.
11. Proton pump inhibitors may be added to the therapy.
12. In long term therapy, dabigatran 110 mg twice a day or rivaroxaban once a day should
be considered for use (compared to VKA lower bleeding incidence, equal stroke rates)
in patients whose bleeding risk is high (especially in the presence of INR labile).
7. New anticoagulant drugs
In AF patients, oral anticoagulation is traditionally done with VKA. However, due to per‐
sonal differences in responses, the need for a balance in dose, labile INR and bleeding risk;
studies have been made on new drugs which do not require follow-up. With these new
drugs such as direct thrombin inhibitor dabigatran, factor Xa inhibitors apixaban and rivar‐
oxaban, the incidence of major bleeding is significantly lower compared to VKA. When Da‐
bigatran 110 mg twice a day is compared with VKA, nonvalvular AF stroke prevention in
the RELY study (Randomized Evaluation of Long-term Anticoagulant Therapy) there is no
difference between stroke and systemic embolism, but the rate of major hemorrhage is
meaningfully less in 110 mg Dabigatran than it is in VKA [18]. In the dose of 150 mg, the
rates of major bleeding and stroke were determined to be similar. In patients with non valv‐
ular AF whose INR values were labile, if they cannot be followed closely and if they do not
have an advanced hepatic and renal problem, dabigatran is an alternative to warfarin. In
non- valvular AF patients, in the ARISTOTLE study done with Apixaban, apixaban is relat‐
ed to lower hemorrhage complication and lower mortality compared to warfarin [19]. In the
ROCKET-AF [20] study, while there was no difference between the major hemorrhage rates
of patients using rivaroxaban and warfarin, the fatal and intracranial hemorrhage rates were
lower in patients using rivaroxaban than in those patients using warfarin. The systemic em‐
boli and stroke prevention rates between the two were equal.
The results of this study are hopeful for long term anticoagulation regimes. There is no suffi‐
cient clinical evidence regarding the fact that these drugs are appropriate for a combination
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therapy (DAPT plus OAC). However, regarding these three studies (RELY, ROCKET-AF,
and ARISTOTLE), when the dual therapy using VKA is compared with dual therapy using
new anticoagulant drugs (apixaban, rivaroxaban, dabigatran), there is no additional differ‐
ence in terms of hemorrhage rate. Thus, when the combination of DAPT with new drugs is
compared to the combination of VKA and DAPT, there is no additional increase in hemor‐
rhage. Nevertheless, in the monotherapy with OAC, the risk of hemorrhage is at its lowest.
However, regarding the safety of the combined use of the new anticoagulant drugs with du‐
al antiplatelet therapy, there is no sufficient evidence regarding long-term use and there is a
need for further studies.
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